Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. - Wikidata - awgldk - TriplyDB

Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.

Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.

http://www.wikidata.org/entity/Q34386029

about

Burkitt lymphoma in adolescents and young adults: management challenges.Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.

P2860

Q30238965-7C17C5FE-A9AD-4151-A825-55BA7996EF6C Q35669884-93D356B3-70D7-44AD-9236-D442E4F6904A Q36052352-D4BD3582-95FD-41B8-87E6-86E0FCA703F3 Q46628337-3CD316BA-4044-4B30-BEA4-8C9B825EAC97 Q52842514-FEFFE84D-EA2A-45F1-9279-72879EA20945

P2860

Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.

http://www.wikidata.org/entity/Q34386029

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical outcome of relapsed o ...... a in children and adolescents.

@ast

Clinical outcome of relapsed o ...... a in children and adolescents.

@en

Clinical outcome of relapsed o ...... a in children and adolescents.

@nl

type

label

Clinical outcome of relapsed o ...... a in children and adolescents.

@ast

Clinical outcome of relapsed o ...... a in children and adolescents.

@en

Clinical outcome of relapsed o ...... a in children and adolescents.

@nl

prefLabel

Clinical outcome of relapsed o ...... a in children and adolescents.

@ast

Clinical outcome of relapsed o ...... a in children and adolescents.

@en

Clinical outcome of relapsed o ...... a in children and adolescents.

@nl

P1433

Q34386029-561BA93B-0076-4EE7-B26A-BD2E8582AA28

P1476

Q34386029-1DE71302-B51F-47E5-82A0-9C708BE2647D

P2093

Q34386029-1C699E76-9529-4743-A298-4D557A3A75C2

Q34386029-2DBEE4CA-A408-4A3C-BBC8-5ADB7DCB145B

Q34386029-42656CF8-EEB0-4EBB-B5E7-02D595AA3E35

Q34386029-5C7509D1-2250-409B-BB2E-DA569F48BE2C

Q34386029-62DAC2D0-06D7-4975-A50F-901F7C1FBE2C

Q34386029-6E40C955-452E-42FC-8253-4FBC6304669E

Q34386029-7B1906FC-C6E8-48A3-B77B-4E7BF29E4A42

Q34386029-81401645-8A21-4B95-9D29-F3F6E1247404

Q34386029-A586B884-C2EE-42EB-86DF-9E965BFC9872

Q34386029-B878720C-7385-4F9A-B5D3-B9E6E8C0D4FE

P2860

Q34386029-09361F52-330B-478D-9839-B7FE6331595A

Q34386029-0D42B16E-3EE7-46ED-8156-85F7710E68E7

Q34386029-0D4A8D55-C762-4056-B9AB-189F2A854CC3

Q34386029-19DB6D3F-25B0-44B1-B988-B10FDA345839

Q34386029-3B9D7B7F-7036-4F50-B7F7-A4DF0AA42F14

Q34386029-4CD0C0FC-E68C-407D-987D-D8213F5BB407

Q34386029-548ADA40-D51B-4F16-AD0B-E9B62A84123B

Q34386029-54BFABEF-CF04-49D4-9D31-826A96F4432D

Q34386029-579F24F9-36E3-4FB0-8DAF-E56A4E85C5B3

Q34386029-717B70C4-C702-4E23-A7B0-F6C6662CBFA5

P304

Q34386029-86D12A9F-84D5-40A2-A1B8-8AFE13D8E6DE

P31

Q34386029-D2F57EB6-7493-4A0E-86DA-43070F59F328

P356

Q34386029-2DF44690-CF1F-4608-831F-FAD33506377C

P433

Q34386029-C5C3974B-2CE4-4398-9285-FFC5A3B8DE46

P478

Q34386029-B1D361DF-51AB-4A3C-BFAB-1CD93007CCC8

P50

Q34386029-0D2897D3-B9C0-43DF-A15B-A808B996D7D1

P577

Q34386029-9AB1409D-39FA-4D53-A7F1-4D0814B27385

P5875

Q34386029-2E757075-363C-45D3-9D0F-307A982F25FB

P698

Q34386029-42BFA401-BAF7-4C62-ACA9-C3DC3EEA4DE5

P921

Q34386029-0D6DDCA2-640D-4273-B4A7-C1A659DF9EB5

Q34386029-6C48236E-DD9F-4E87-BD1A-39288CEC986F

Q34386029-B429B6BF-D975-4F83-B1A8-9C413AAE5FAF

P932

Q34386029-F1422C11-A239-4EEC-AF5F-C9253403587F

P356

P1433

Cancer Research and Treatment

P1476

Clinical outcome of relapsed o ...... a in children and adolescents.

@en

P2093

Eun Sil Park

http://www.w3.org/2001/XMLSchema#string

Hee Jo Baek

http://www.w3.org/2001/XMLSchema#string

Hee Young Shin

http://www.w3.org/2001/XMLSchema#string

Hong Hoe Koo

http://www.w3.org/2001/XMLSchema#string

Hoon Kook

http://www.w3.org/2001/XMLSchema#string

Hyeo Seop Ahn

http://www.w3.org/2001/XMLSchema#string

Hyery Kim

http://www.w3.org/2001/XMLSchema#string

Hyo Sun Kim

http://www.w3.org/2001/XMLSchema#string

Hyoung Jin Kang

http://www.w3.org/2001/XMLSchema#string

Ji Won Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08.

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.

A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.

Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.

Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.

P304

358-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4143/CRT.2013.047

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264091871

http://www.w3.org/2001/XMLSchema#string

P698

25043820

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma

P932

4206068

http://www.w3.org/2001/XMLSchema#string